baricitinib; biosimilar agent; chloroquine; colchicine; favipiravir; hydroxychloroquine; ivermectin; molnupiravir; orphan drug; remdesivir; SARS-CoV-2 vaccine; sorafenib; tocilizumab; clinical research; coronavirus disease 2019; drug approval; drug industry; drug marketing; drug repositioning; drug use; editorial; Food and Drug Administration; government; human; incentive; India; liver cell carcinoma; muscular dystrophy; pandemic; patent; rare disease; renal cell carcinoma; scientist; Severe acute respiratory syndrome coronavirus 2; sickle cell anemia; tax credit; thyroid papillary carcinoma; United States